Neuroblastoma
High-risk and relapsed disease: MYCN amplification, ALK mutations and anti-GD2 therapy.
Each dot is one target. Higher means stronger genetic evidence in people (inherited variants or tumour mutations, whichever is stronger). Further right means more evidence from drugs already in trials or approved.
Scores run from 0 to 1 and are Open Targets' summary of how much evidence exists, not the chance a drug will work. The dividing lines sit at 0.5. Hover a dot for its numbers, click it for the target's page. Source: Open Targets Platform, fetched live.
The 18 targets in the top-left of the chart, strongest genetic evidence first. Click one for its drugs, tractability and other cancers.
All 50 targets, by type of evidence
Ranked by overall score for neuroblastoma on the Open Targets Platform. Darker cells mean stronger evidence of that type.
Peds RMTLmarks the 6 of these targets on the FDA's Pediatric Relevant Molecular Target List: a drug against one of them can be required to be studied in children under the RACE for Children Act.
| Target | Overall | Germline genetics | Somatic | Clinical | genetic literature | Pathways | Literature | Animal models |
|---|---|---|---|---|---|---|---|---|
| ALKPeds RMTL ALK receptor tyrosine kinase | 0.84 | 0.97 | 0.81 | |||||
| PHOX2B paired like homeobox 2B | 0.63 | – | 0.30 | |||||
| BARD1 BRCA1 associated RING domain 1 | 0.61 | 0.86 | 0.53 | |||||
| LMO1 LIM domain only 1 | 0.48 | 0.74 | – | |||||
| ATRXPeds RMTL ATRX chromatin remodeler | 0.47 | – | 0.60 | |||||
| SLC6A2 solute carrier family 6 member 2 | 0.47 | – | – | |||||
| EWSR1 EWS RNA binding protein 1 | 0.46 | – | 0.72 | |||||
| KIF1B kinesin family member 1B | 0.46 | 0.56 | – | |||||
| RARA retinoic acid receptor alpha | 0.46 | – | 0.30 | |||||
| CSF3R colony stimulating factor 3 receptor | 0.45 | – | 0.30 | |||||
| FLI1 Fli-1 proto-oncogene, ETS transcription factor | 0.45 | – | 0.72 | |||||
| PTPN11Peds RMTL protein tyrosine phosphatase non-receptor type 11 | 0.44 | – | 0.55 | |||||
| TOP2B DNA topoisomerase II beta | 0.43 | – | – | |||||
| TOP2A DNA topoisomerase II alpha | 0.42 | – | – | |||||
| TUBB2B tubulin beta 2B class IIb | 0.42 | – | – | |||||
| TUBB tubulin beta class I | 0.42 | – | – | |||||
| TUBA1A tubulin alpha 1a | 0.42 | – | – | |||||
| TUBA1B tubulin alpha 1b | 0.42 | – | – | |||||
| TOP1 DNA topoisomerase I | 0.42 | – | – | |||||
| TUBB3 tubulin beta 3 class III | 0.41 | – | – | |||||
| TUBB4A tubulin beta 4A class IVa | 0.41 | – | – | |||||
| TUBB2A tubulin beta 2A class IIa | 0.41 | – | – | |||||
| TUBA4A tubulin alpha 4a | 0.41 | – | – | |||||
| TUBB1 tubulin beta 1 class VI | 0.41 | – | – | |||||
| TUBB4B tubulin beta 4B class IVb | 0.41 | – | – | |||||
| TUBB6 tubulin beta 6 class V | 0.41 | – | – | |||||
| TUBB8 tubulin beta 8 class VIII | 0.41 | – | – | |||||
| TUBA3E tubulin alpha 3e | 0.41 | – | – | |||||
| TUBA3C tubulin alpha 3c | 0.41 | – | – | |||||
| TUBA1C tubulin alpha 1c | 0.41 | – | – | |||||
| NF1 neurofibromin 1 | 0.41 | – | 0.49 | |||||
| RARG retinoic acid receptor gamma | 0.41 | – | – | |||||
| RARB retinoic acid receptor beta | 0.41 | – | – | |||||
| SMARCA4 SWI/SNF related BAF chromatin remodeling complex subunit ATPase 4 | 0.40 | 0.44 | 0.53 | |||||
| TP53Peds RMTL tumor protein p53 | 0.39 | 0.27 | 0.48 | |||||
| IDH2Peds RMTL isocitrate dehydrogenase (NADP(+)) 2 | 0.39 | – | 0.61 | |||||
| CSF2RB colony stimulating factor 2 receptor subunit beta | 0.39 | – | – | |||||
| CSF2RA colony stimulating factor 2 receptor subunit alpha | 0.38 | – | – | |||||
| PIK3CAPeds RMTL phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | 0.38 | – | 0.57 | |||||
| FBN2 fibrillin 2 | 0.38 | – | 0.61 | |||||
| IL2RG interleukin 2 receptor subunit gamma | 0.37 | – | – | |||||
| FEV FEV transcription factor, ETS family member | 0.37 | – | 0.61 | |||||
| IL2RB interleukin 2 receptor subunit beta | 0.37 | – | – | |||||
| IL2RA interleukin 2 receptor subunit alpha | 0.37 | – | – | |||||
| BRCA2 BRCA2 DNA repair associated | 0.37 | 0.19 | 0.46 | |||||
| IL15RA interleukin 15 receptor subunit alpha | 0.37 | 0.59 | – | |||||
| SALL4 spalt like transcription factor 4 | 0.36 | 0.58 | – | |||||
| RPTN repetin | 0.35 | 0.58 | – | |||||
| ARHGEF40 Rho guanine nucleotide exchange factor 40 | 0.35 | 0.58 | – | |||||
| APC APC regulator of Wnt signaling pathway | 0.35 | – | 0.57 |
4 biomarkers in Neuroblastoma have validated or clinical evidence in CIViC
Accepted evidence from CIViC, the open (CC0) expert-curated knowledgebase, searched by the disease name “Neuroblastoma”. Level A is validated (for example in guidelines or an approval), level B comes from clinical trials or studies. 28 accepted items exist; the first 28 were read. This is the published evidence, not treatment advice.
- MYCN Amplification level A
- FOXR2 Rearrangement level B
- CASP8 D302H level B
- NTRK1 Overexpression level B